The FDA now requires a boxed warning for montelukast (Singulair) due to the risk of neuropsychiatric events associated with the drug. The FDA said Wednesday it will now require a boxed warning—the ...

WARNING: If you experience behaviour and mood-related changes including suicidal thoughts and actions while taking MONTELUKAST VIATRIS (see "Behavioural and mood related changes under Side Effects"), ...

Two advisory committees of the US Food and Drug Administration (FDA) met jointly to discuss a safety review of neuropsychiatric events in children taking montelukast (Singulair, Merck) for asthma and ...

AUSTIN, Texas — New warnings for a popular asthma and allergy drug after the FDA links the medicine to mental health issues. The FDA issued a black box warning for Singulair, or the generic form ...

Please provide your email address to receive an email when new articles are posted on . There were no differences in mental health outcomes between montelukast and long-acting beta-agonists.

October 2, 2006 ---- Health Canada has approved a new indication for montelukast sodium, allowing its use for the relief of symptoms associated with seasonal allergic rhinitis in patients aged 15 ...

PITTSBURGH, Aug. 7, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) ...

A meta-analysis of anti-inflammatory agents for the treatment of pediatric obstructive sleep apnea (OSA) found that montelukast plus intranasal steroids or montelukast alone may benefit patients with ...

A 14-day course of the oral anti-inflammatory drug montelukast didn't shorten symptom duration in nonhospitalized US adults with mild or moderate COVID-19, finds a randomized controlled clinical trial ...

KENILWORTH and WHITEHOUSE STATION, N.J., Aug. 28 -- Schering-Plough/Merck Pharmaceuticals (SPM) today announced that the New Drug Application filing for loratadine/montelukast has been accepted by the ...

KENILWORTH and WHITEHOUSE STATION, N.J., April 25 -- Schering-Plough/MERCK Pharmaceuticals (SPM) today confirmed that it received a not-approvable letter from the U.S. Food and Drug Administration ...

The risk of a mixing-up the treatments is especially high for pregnant women, says the Food and Drug Administration (FDA), as losartan is indicated to treat high blood pressure and could harm or kill ...